利图西马布在新发的一般化肌痛性严重性中:RINOMAX临床试验的长期随访
Jing Wu1,2,3, Ann Eriksson-Dufva2,3,4, Anna Budzianowska5
1Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
European journal of neurology
|November 6, 2025
概括
利图西马布 (RTX) 显示在全性肌痛性肌痛性肌痛症 (MG) 中长达24个月的持续益处,减少了疾病活动和治疗负担. 然而,B细胞枯竭的感染风险需要仔细监测.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 此前,RINOMAX试验显示,Rituximab (RTX) 优于新发性全身性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛.
- 在一般性MG中,RTX的长期益处风险数据仍然有限.
研究的目的:
- 评估Rituximab在一般化骨髓灰质炎的长期疗效和安全性.
- 评估RTX对疾病活动,治疗负担和长期住院率的影响.
主要方法:
- 在RINOMAX试验中,47名参与者随机获得中度至严重的通用MG到RTX或安慰剂.
- 瑞典MG注册表的数据被用于追踪住院,救援治疗和疾病活性评分 (QMG) 长达5年的时间.
- 在早期RTX暴露,延迟RTX和安慰剂组之间进行了比较分析.
主要成果:
- 与安慰剂相比,Rituximab (RTX) 治疗在12个月和24个月后导致QMG得分显著降低.
- 救援治疗的发生率在RTX手臂 (0.09/人/年) 与安慰剂 (0.16/人/年) 相比,在数值上较低.
- 与延迟RTX相比,早期RTX暴露与QMG得分,住院 (HR 0.24) 和救援治疗的降低有关.
结论:
- 利图西马布在一般性MG中显示出有利的长期疾病轨迹的潜力,持续低的疾病活性和治疗负担.
- 虽然RTX显示有好处,但与B细胞枯竭相关的严重感染风险仍然是一个重大问题.
- 需要进一步的研究来优化RTX的使用,并管理一般性MG患者的潜在不良事件.
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:22Myocarditis IV: Nursing Management
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...